Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease

Summary

This is a pivotal Phase 2/3, double-blind, placebo-controlled study of epetraborole + OBR (Optimized Background Regimen) versus placebo + OBR in patients with treatment-refractory MAC lung disease. This study will enroll adult patients with treatment-refractory MAC lung disease who meet all eligibility criteria (including clinical, radiographic, and microbiological criteria).

Timeline

Start

2022-05-20

Primary completion

2024-12-18

Completion

2024-12-18

Drugs

Indications